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Abstract
Background and Objective—Congenital myasthenic syndromes are rare inherited disorders 
characterized by fatigable weakness caused by malfunction of the neuromuscular junction. We 
performed whole exome sequencing to unravel the genetic aetiology in an English sib pair with 
clinical features suggestive of congenital myasthenia.
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Methods—We used homozygosity mapping and whole exome sequencing to identify the 
candidate gene variants. Mutant protein expression and function were assessed in vitro and a 
knockdown zebrafish model was generated to assess neuromuscular junction development.
Results—We identified a novel homozygous missense mutation in the SLC25A1 gene, encoding 
the mitochondrial citrate carrier. Mutant SLC25A1 showed abnormal carrier function. SLC25A1 
has recently been linked to a severe, often lethal clinical phenotype. Our patients had a milder 
phenotype presenting primarily as a neuromuscular (NMJ) junction defect. Of note, a previously 
reported patient with different compound heterozygous missense mutations of SLC25A1 has since 
been shown to suffer from a neuromuscular transmission defect. Using knockdown of SLC25A1 
expression in zebrafish, we were able to mirror the human disease in terms of variable brain, eye 
and cardiac involvement. Importantly, we show clear abnormalities in the neuromuscular junction, 
regardless of the severity of the phenotype.
Conclusions—Based on the axonal outgrowth defects seen in SLC25A1 knockdown zebrafish, 
we hypothesize that the neuromuscular junction impairment may be related to pre-synaptic nerve 
terminal abnormalities. Our findings highlight the complex machinery required to ensure efficient 
neuromuscular function, beyond the proteomes exclusive to the neuromuscular synapse.
Keywords
Congenital myasthenic syndrome; neuromuscular junction; mitochondrial citrate carrier; 
SLC25A1
INTRODUCTION
Congenital myasthenic syndromes (CMS) are a group of inherited neuromuscular disorders 
in which the integrity of the neuromuscular junction (NMJ) is compromised [1]. The clinical 
hallmark of these syndromes is fatigable weakness, which is often treatable. Most of CMS 
patients present with fluctuating ocular, bulbar, respiratory and limb weakness [2, 3]. Over 
the past 25 years, more than 19 genes have been implicated in congenital myasthenic 
syndromes [4, 5]. These usually express proteins involved in neuromuscular synapse 
development and function; and most mutations identified so far have involved post-synaptic 
proteins.
However, in spite of recent progress, a proportion of congenital myasthenic syndrome 
patients remain genetically undiagnosed [2]. Thus, one can speculate that some of these 
undiagnosed patients may harbour very rare private mutations in a particular gene. 
Alternatively, these patients may have mutations in genes encoding ubiquitous proteins that 
can primarily present as an NMJ defect but may also have a much broader spectrum of 
disease. A good example includes the recently discovered CMS related to mutations in 
genes that were until then implicated in congenital glycosylation disorders [6, 7]. Another 
example includes mutations in PLEC1 and LAMB2 genes in which mutations can lead to a 
CMS phenotype combined with skin or kidney disease respectively [8, 9].
Whilst mitochondrial gene defects can cause a myriad of neurological disorders including 
myopathies and neuropathies, these have not been specifically implicated in defects of the 
neuromuscular junction [10, 11].
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SLC25A1 is a mitochondrial citrate carrier believed to be a key player in fatty acid and 
sterol biosynthesis, gluconeogenesis and glycolysis [12]. More recently, it has been 
proposed that it may also play a role in the maintenance of chromosome integrity and in the 
regulation of autophagy [13, 14].
In the mitochondria, SLC25A1 mediates the exchange of mitochondrial citrate/isocitrate 
with cytosolic malate. The exported citrate is cleaved into acetyl-coenzyme-A and 
oxaloacetate by ATP-citrate lyase [12, 15]. Acetyl-coenzyme A is the main substrate of lipid 
and sterol biosynthesis in the cell while oxaloacetate is usually reduced to malate and 
diverted back into the mitochondria for further exchange with mitochondrial citrate. Citrate 
can also inhibit cytosolic phosphofructokinase 1, thus indirectly influencing the rate of 
glycolysis. Both citrate and malate are involved in regulating NADPH content in the cell 
[15, 16].
The recent discovery of several patients harbouring mutations in this mitochondrial carrier 
has confirmed that this is a protein of critical biological importance in humans [17, 18]. 
Indeed SLC25A1 dysfunction was shown to interfere with brain, eye and perhaps 
neuromuscular development, in addition to causing a distinctive urinary organic acid profile. 
Whether this metabolic disturbance itself is sufficient to explain the phenotype is unclear at 
present. However, it is likely that other factors like oxidative stress, ROS toxicity and 
NADPH content are also relevant.
We performed whole exome sequencing in an affected sib pair from a consanguineous 
family from Northern England. The patients had remained genetically undiagnosed for more 
than 23 years, having had a suspected clinical diagnosis of congenital myasthenia with a 
reported response to pharmacotherapy.
MATERIALS AND METHODS
Patient data
Patients were selected from the Newcastle MRC Neuromuscular Centre, Institute of Genetic 
Medicine, Newcastle upon Tyne. Our patients were 2 Caucasian siblings born to two healthy 
consanguineous parents (first cousins), from Newcastle in the North of England. The index 
case was a male patient who presented with fatigable weakness since early infancy mainly 
involving his limbs. Neurophysiological studies showed no evidence of neuropathy or 
myopathy. Although there was no decrement on repetitive nerve stimulation, there was 
marked jitter in several muscles in keeping with impaired neuromuscular junction 
transmission. His sister presented in a similar fashion but exhibited moderate intellectual 
disability. Given the positive family history, evidence of fatigable weakness with abnormal 
jitter, a diagnosis of CMS was suspected. Appropriate consent for research was obtained 
from each patient and any family member involved in this study.
Genomic DNA was extracted from venous blood taken from both siblings and unaffected 
family members, by automated DNA extraction on the M48 Bio Robot using the MagAttract 
DNA blood Mini M48 kit (Qiagen 951336) as part of the routine service performed by the 
Northern Genetics Service molecular laboratory.
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Study of the patient neuromuscular junction
Repetitive nerve stimulation and single fibre EMG (SFEMG) were carried out on the index 
case at age 20 and repeated at 21 years. 3 Hz stimulation was used to search for decrement 
and we checked for facilitation after 20 sec of voluntary maximum contraction.
The number of endplate AChR was determined as previously described [19]. Briefly, muscle 
bundles were dissected, labelled with 125I-a-BuTX, prior to staining for 
acetylcholinesterase. The number of endplates in a given region was determined in 
combination with respective level of 125I-a-BuTX binding to generate the number of 
receptors per endplate. 35 NMJ were checked to determine (miniature endplate potentials 
(MEPPS) and quantal content with between 1 and 62 MEPPS per NMJ.
Homozygosity mapping
In order to identify the chromosomal location of the disease causing mutation in this family, 
we carried out genome wide genotyping of SNPs using Illumina 300K chip (Illumina, San 
Diego, Ca). This was performed to identify regions of homozygosity shared by both affected 
siblings, since we presumed the inherited disease to be recessive caused by a homozygous 
mutation segregating on the same ancestral haplotype.
Whole exome sequencing and data analysis
Given that the family history was highly suggestive of autosomal recessive inheritance 
(healthy parents, two affected children and parental consanguinity), and that most CMS are 
recessive in inheritance, we applied the recessive model looking for genes containing 
homozygous or at least 2 heterozygous changes shared between siblings (see supplementary 
material for the details of exome filtering pipeline).
CGH array analysis
CGH array was carried out to analyse copy number variations on the female patient who 
exhibited intellectual disability. CytoChip ISCA 180 K V1.0 oligonucleotide array 
(BlueGnome) was used according to the manufacturer’s instructions (BlueGnome). RsaI and 
AluI digested DNA products (patient’s DNA as well as reference DNA) from peripheral 
blood were labelled by random priming using either Cy3-dUTP or Cy5-dUTP) and 
hybridized at 65°C for 24 h. Scanning and image acquisition was done on an Agilent 
microarray scanner. Data analysis was performed using BlueFuse Multi software 
(BlueGnome).
Construction of the expression plasmids and bacterial expression
The coding sequence of the yeast orthologue citrate carrier CIC (CTP1, NM_001178639.1) 
was amplified from S. cerevisiae genomic DNA via PCR and the mutations were introduced 
by site-directed mutagenesis as described in QuikChange® Site-Directed Mutagenesis Kit 
from Stratagene. Ctp1p and its mutated form (p.R241Q, p.R276H and p.G117D) were 
overexpressed as inclusion bodies in the cytosol of E. coli strain BL21 (DE3). Inclusion 
bodies were purified on a sucrose density gradient and washed at 4°C, first with Tris-EDTA 
buffer (10 mM Tris–HCl, 1 mM EDTA, pH 7.0), then twice with a buffer containing Triton 
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X-114 (3%, w/v), 1 mM EDTA, 20 mM Na2SO4 and 10 mM PIPES pH 7.0, and finally with 
the Tris-EDTA buffer pH 7.0. The proteins were solubilized in 1.7% sarkosyl (w/v). 
Eventual small residues were removed by centrifugation (20800 × g for 10 min at 4°C).
Reconstitution of the recombinant proteins into liposomes and transport assays
The recombinant proteins solubilized in sarkosyl were reconstituted by cyclic removal of 
detergent as described [20] with some modification. The reconstitution mixture consisted of 
phospholipids in the form of sonicated liposomes (10 mg), protein solution (25 μl, about 9 
μg), 10% Triton X-114 (70 μl), 10 mM citrate (35 μl), cardiolipin (0.7 mg), 10 mM PIPES/
NaOH pH 7.0 and water (final volume 700 μl). The mixture was recycled 13-fold through an 
Amberlite column pre-equilibrated with 10 mM PIPES-NaOH (pH 7.0) and 50 mM NaCl. 
All operations were performed at 4°C except the passages through Amberlite, which were 
carried out at room temperature. Approximately 20% of WT or mutated CIC proteins were 
reconstituted. External citrate was removed from proteoliposomes on Sephadex G-75 
columns pre-equilibrated with 50 mM NaCl and 10 mM PIPES at pH 7.0 (buffer A). 
Transport at 25°C was started by adding 0.1 mM [14C] Citrate (from PerkinElmer, Inc) to 
proteoliposomes and terminated by addition of 20 mM pyridoxal 5′ phosphate and 20 mM of 
bathophenanthroline. In controls, inhibitors were added with the labelled substrate. The 
external substrate was removed by Sephadex G-75 columns pre-equilibrated with buffer A, 
and the entrapped radioactivity was counted. The experimental values were corrected by 
substracting control values and the initial transport rate was calculated from the time-course 
of substrate uptake by proteoliposomes [21].
Mitochondrial membrane potential assessment in fibroblasts
Fibroblasts from the affected sibling harbouring the SLC25A1 variant c.740G > A; p.R247Q 
and control fibroblasts were grown in DMEM (high glucose). Membrane potential was 
measured by fluorescence microscopy using the tetramethylrhodamine methyl ester 
(TMRM) probe [22], while mitochondrial morphology was investigated using MitoTracker® 
Red CMXRos. MitoTracker® Red CMXRos and tetramethylrhodamine methyl ester 
(TMRM) were purchased from Life Technologies.
Fluorescent images of treated cells were acquired and fluorescence intensities were 
analyzed, as previously described [23], using a Zeiss Axiovert 200 microscope equipped 
with a Photometrics Cascade 512B CCD camera (Roper Scientific) and the MetaFluor 
software (Universal Imaging).
Western blotting
Immunoblot analysis was performed using 100 × 103 cells (patient and control fibroblast). 
The cells were rinsed with ice-cold PBS and lysed using RIPA buffer. Total proteins were 
heated at 100°C for 5 min, separated by SDS-PAGE and transferred to nitrocellulose 
membranes. The membrane was then incubated at room temperature with anti-SLC25A1 
polyclonal antibodies raised in rabbit against recombinant rat SLC25A1 carrier or mouse 
monoclonal antibodies against the β subunit of human F1-ATPase (BD Biosciences). 
Antigen–antibody complexes were detected using anti-rabbit or mouse IgG-coupled 
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horseradish peroxidase (Pierce, Thermo Scientific), in combination with the ECL system 
(Merk Millipore).
Multiple sequence alignment and evolutionary pressure analysis
A multiple sequence alignment of citrate carrier (CIC) orthologs from various species and 
other mitochondrial carriers was obtained using ClustalW [24]. The functional or structural 
relevance of the mutated residues of the mitochondrial citrate carrier protein was estimated 
according to a scoring system based on the evolutionary pressure acting on each amino acid 
as described previously [25].
SLC25A1 knockdown in zebrafish embryos
A BLAST search of zebrafish transcripts with the human SLC25A1 protein sequence as 
input revealed the presence of three homologues in the zebrafish genome: two on 
chromosome 10: SLC25A1a (NM_200607), SLC25A1b (XM_003199276.2) and one on 
chromosome 8 (SLC25A1c). Only SLC25A1a and SLC25A1b from chromosome 10 are 
expressed in zebrafish (Supplementary Figure 1).
Zebrafish husbandry and observation
The Golden strain (slc24a5b1/+) of zebrafish was used in this study (Zebrafish International 
Resource Centre (ZIRC), Oregon). Zebrafish embryos were raised at 28.5°C and staged in 
hours or days post-fertilization (hpf or dpf) according to standard procedures. Video 
recordings of embryos and larvae were taken with a Leica dissection stereomicroscope 
equipped with a Chameleon digital camera (model CMLN-13S2M, Chameleon). Touch-
evoked swimming response of embryos was elicited by touching the head or the tail of the 
embryos with a fine pipette tip. Light microscope images of injected and non-injected 
embryos were taken with a digital camera (model LEICA DFC 420C) mounted on a Leica 
dissection stereomicroscope. Procedures involving experimentation on animal subjects were 
done in accordance with the local institutional guide.
Antisense morpholino oligonucleotide knockdown
Antisense morpholino oligonucleotides (MOs) were purchased from Gene Tools LLC 
(Pilomath, OR). The MOs were designed with the mRNA sequence of the zebrafish 
SLC251A orthologues and genomic sequences available from public databases (SLC25A1A 
GeneID: 393579, accession number: NM_200607.1) and (SLC25A1B GeneID: 795332, 
accession number: XM_003199276.2) and the corresponding genomic DNA sequence 
obtained from the zebrafish chromosome 10 assembly.
We established two MOs, one per gene orthologue. Both MOs are splice-blocking and 
directed against the splice donor site of exon 3. The following two morpholinos were used: 
(MO1: zSLC25A1a 5′-AGATGAATCTTTCTTACCGTACTGC-3′ and MO2: zSLC25A1b 
5′-GCGGGTTAGGAAACACTCACCTC AC-3′). Both MOs are expected to interfere with 
the splicing process and lead to a disruption of the protein open reading frame and premature 
translation termination after 25 missense amino acids. The Gene Tools standard control MO 
(5′-CCTCTTACCTCAGTTACAATTTATA-3′) targeting a human beta-haemoglobin gene 
was used as a negative control for the effects of MO injection. We also used the Gene Tools 
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anti-p53 MO (5′-GCGCCATTGCTTTGCAAGAATTG-3′) to suppress any non-specific 
apoptotic effects that can be induced by some MOs.
MOs were suspended in 1x Danieau solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 
0.6 mM Ca(NO3)2, 5 mM HEPES; pH 7.6) with phenol red as an injection indicator.
Embryos were injected with both morpholinos separately to determine the optimal 
concentration to produce the best range of phenotypes and then with both MOs 
simultaneously. 5 ng SLC25A1a MO and 2.5 ng SLC25A1b produced the best range of 
phenotypes. Four independent MO injection experiments were performed for each MO and 
at least 500 injected embryos were evaluated in total for each MO.
RNA isolation and RT-PCR
RNA from approximately 30 zebrafish embryos was isolated with Trizol reagent 
(Invitrogen, Life Technologies) following the manufacturer’s instructions. Reverse 
transcription was performed with 1 or 2 μg total RNA as template with the Superscript III 
First-Strand Synthesis System (Invitrogen, Life Technologies) and MolTaq DNA 
polymerase (Molzym). Regions of interest were amplified with compatible primers.
Immunofluorescence staining
Whole-mount immunofluorescence staining and imaging of zebrafish embryos was 
conducted as previously described. In brief, NMJ were visualized with Alexa Fluor® 594 
conjugated alpha-bungarotoxin (Invitrogen, Life Technologies, 1 mg/ml) and a mouse 
monoclonal anti-SV2 (synaptic vesicle protein 2) antibody (Developmental Studies 
Hybridoma Bank, Iowa City, IA; dilution 1:200). Alexa Fluor® 594 conjugated phalloidin 
(Sigma-Aldrich) was used at a concentration of 5 μg/ml to label actin.
RESULTS
Clinical phenotype
This was a consanguineous family of Caucasian origin from the north of England with 2 
affected siblings and one healthy offspring. Both parents were reportedly healthy. The index 
case is a 33-year-old man who was the product of normal pregnancy and birth but displayed 
some speech and motor developmental delay. In early childhood, he developed intermittent 
leg weakness, which was exercise induced and improved with rest. He had no ocular, bulbar 
or respiratory difficulties. He had mild learning difficulties but was able to attend 
mainstream schooling and settle in full time employment. His neuromuscular symptoms 
have been stable over the years. Of note, he recently developed obsessive-compulsive 
tendencies. Examination showed mild bilateral ptosis but no ophthalmoplegia. He has 
dysarthria with fatigable speech. Muscle tone and power were normal at rest. However, 
there was fatigability with exercise. He had bilateral pes cavus as well as calf hypertrophy 
bilaterally. Reflexes were reduced at rest with clear potentiation with exercise (Table 1).
The sister, who is now 19 years, is the product of normal pregnancy and birth. She had 
delayed psychomotor milestones, more marked than her brother. She developed recurrent 
falls in early infancy with clear fatigable weakness in all her limbs. She complained of 
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intermittent double vision but she had no bulbar or respiratory difficulties. The course of her 
illness was static. Examination showed some facial weakness with no ophthalmoplegia or 
ptosis. She had mild neck flexion weakness with fatigable arm and leg weakness. She is 
ambulant. Reflexes were normal. This patient currently attends a special need college (Table 
1).
Neurophysiology was performed in consecutive years when the index patient was aged 20 
and 21 years with similar outcome. At both examinations, repetitive nerve stimulation of 
ADM (abductor digiti minimi) and anconeus at 3 Hz stimulation showed no decrement of 
CMAP (compound muscle action potential) and no facilitation of CMAP after maximum 
voluntary contraction for 20 sec. SFEMG (single fibre EMG) on EDC (extensor digitorum 
communis) showed 72% of potential pairs have increased jitter or jitter with blocking: −25% 
were normal, 52% showed increased jitter, 20% showed block, from 25 pairs sampled. 
Analysis of jitter showed a MCD (mean consecutive difference) of 78.5 ± 44.4 micros from 
non-blocking pairs. At age 21, SFEMG on EDC showed 81% of potential pairs have 
increased jitter or jitter with blocking: 19% were normal, 62% showed increased jitter, 19% 
were blocking, from 16 pairs. MCD was 71.6 micros.
Muscle biopsy was normal although electron microscopy of an earlier muscle biopsy 
suggested enlarged mitochondria and an increase in their number. We were unable to access 
the biopsy to obtain further details. Only a crude determination of endplate morphology was 
obtained at the time. In some cases the endplates appeared enlarged, but there are not 
detailed studies of this. Analysis of an anconeus muscle biopsy showed normal endplate 
AChR number. Consistently MEPP amplitude and quantal content in in vitro 
electrophysiology was within the normal range.
Muscle histology was normal with normal respiratory chain enzyme activity and no 
evidence of mitochondrial DNA deletions on muscle analysis. Blood and CSF lactate levels 
were normal. Genetic testing for MELAS, MERRF, LHON, NARP was negative. Free and 
total carnitine levels were normal. Acetylcholine receptor antibodies were negative. CT and 
more recently MRI of the brain with spectroscopy were normal.
The index case was initially treated with pyridostigmine with no clear benefit after which he 
was instigated on 3,4-DAP with a favourable response. His sister received pyridostigmine 
since early childhood, which she continues to this date. It is unclear whether she has any 
benefit from this treatment.
While the index case had normal karyotype, we identified a 30.4 Mb deletion Xq25 to Xq28, 
Position 122,440,897-154,886,079 using CGH array in the affected sister. The parents have 
not yet been tested for this deletion.
The third patient was described earlier and is now aged 3 years [17]. She presented soon 
after birth with poor sucking, recurrent apnoea, apathy and hypotonia. Corpus callosum 
agenesis and optic atrophy were found. Subsequently, psychomotor developmental delay, 
reduced spontaneous movement as well as seizures were documented. Recurrent apnoea and 
poor respiratory effort necessitated tracheostomy. She is now ventilator-dependent. Urinary 
organic acid analysis revealed a large peak of 2-hydroxyglutaric acid and Krebs cycle 
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intermediates. Mitochondrial functions in cultured skin fibroblasts disclosed decreased 
growth in glucose free medium, increased ROS production and decreased mitochondrial 
membrane potential but normal ATP content. Exome sequencing led to the identification of 
two SLC25A1 variants, chr.22:19163734 C->T resulting in (p.R282H) and chr.22:19165292 
C->T resulting in (p.G130D). Kinetic studies using mutant recombinant protein into 
liposomes showed complete loss of transport function for the former variant and only a 
small residual activity for the latter. Single-fibre EMG at the age of 2 years revealed 
markedly increased jitter and blocking. The myasthenic symptoms did not fluctuate and did 
not improve with 3,4-DAP, pyridostigmine and ephedrine (Table 1).
Our two affected siblings were born to healthy consanguineous parents indicating a 
recessive pattern of inheritance. The following CMS gen6es were excluded by targeted 
linkage analysis: COLQ, CHRNA1, CHRNB1, CHRNE, CHAT, RAPSN, MUSK, SCN4A, 
DOK7 and GFPT1. Sanger sequencing was carried out to further exclude CHRNA1, 
CHRNB1, CHRND, CHRNE, RAPSN, CHAT, DOK7 and COLQ.
Identification of mutations in SLC25A1 gene
Homozygosity mapping by genome wide SNP genotyping revealed 4 large homozygous 
blocks on chromosome 5 (7.97 Mb); chromosome 13 (19.43 Mb); chromosome 16 (17.02 
Mb) and chromosome 22 (10.62 Mb) shared by both siblings. Because these homozygous 
blocks were very large and contained many genes, we decided to proceed with whole exome 
sequencing in both siblings.
Whole exome sequencing generated an average of 8.73 gigabases (Gb) of mappable 
sequences per patient and 53.92% of reads mapped to targets. 87% of targeted variants had a 
10 fold coverage, which was used for variant calling in our filtering pipeline. Filtering of 
variants shared by both siblings by restricting our search to coding, rare (frequency <1%), 
predicted to be deleterious changes, allowed us to shortlist one homozygous variant in the 
SLC25A1 gene (exon7: c.740G > A; p.R247Q, GenBank: NM_005984). This variant was 
located in the large homozygous block on chromosome 22 and led to the substitution of a 
highly conserved positively charged arginine residue to a neutral glutamine residue. It is 
worth noting that the same mutation was identified using whole genome sequencing of the 
older sibling. A second rare variant was identified in CLTL1, c.719A > G; p.N240S 
(rs147685377). However, this variant was identified at frequencies between 0.1% and 0.7% 
in public and “in house” databases suggesting that this is likely to be a benign variant.
The SLC25A1 variant (c.740G > A; p.R247Q) segregated in the family according to an 
autosomal recessive transmission pattern. Both parents were heterozygous for the mutant 
allele whilst the unaffected brother was homozygous for the wild type allele.
We further screened a total of 58 patients from our CMS cohorts (Munich, Newcastle, 
Oxford), but did not identify additional pathogenic variants in SLC25A1. Exome sequencing 
of 100 undefined neuromuscular cases including CMS cases did not identify any other 
SCL25A1 variants.
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After obtaining the above described results, we proceeded to investigate a neuromuscular 
transmission defect in a Jewish Ashkenazi patient (patient 3 described above), previously 
described by us with compound heterozygous disease-causing mutations of SLC25A1 gene 
[17].
Biochemical characterization of the SLC25A1 variants
SLC25A1 consists of eight exons which encode the mitochondrial citrate carrier, a 311 
amino acid protein. The percentage of identical amino acids between the yeast and the 
mammalian orthologous mitochondrial carriers is generally not much higher than that 
observed between the different members of the mitochondrial carrier family (25–30% of 
identical amino acids; [26]). Notably the yeast Ctp1p shares 37% of sequence identity (52% 
of sequence similarity) with the human citrate transporter coded by SLC25A1. Nonetheless, 
S. cerevisae has been shown to be useful for studying the functional effect of pathogenic 
mutations in human mitochondrial transporters that proved difficult to be over-expressed in 
bacteria [17, 27]. As shown in Fig. 1A, arginine 247 is highly conserved in SLC25A1 of 
fungi and metazoan and also conserved in several other mitochondrial carriers (Fig. 1B). 
This residue belongs to the transmembrane helix 5 and corresponds to the second basic 
amino acid of the sequence motif PX[D/E]XX[K/R]X[K/R], which is characteristic of 
members of the mitochondrial carrier family [28]. By comparison with the crystallized 
structure of the ADP/ATP carrier [29] it is observed that R247, together with the two 
residues of the citrate carrier located at the same height on transmembrane helix 1 (Q52) and 
3 (K149), is involved in ionic interactions with the acidic residues of the second part of the 
MCF sequence motif [D/E]GxxxxAr[R/K]G at the beginning of even transmembrane helices 
(Fig. 1c, Supplementary Figures 2, 3). These intra-repeat interactions participate in alternate 
closing and opening of the carrier on the matrix side during the substrate transport cycle 
[30].
Kinetic analysis of the R241Q Ctp1p mutant was performed upon reconstitution of purified 
recombinant protein into liposomes. As shown in Fig. 2, the substitution of R241, 
corresponding to R247 in human SLC25A1, with glutamine causes a strong impairment of 
transport activity compared to WT Ctp1p even though a significant residual activity was 
conserved.
This decrease could only in part be compensated by an increase (approximately 30%) of 
SLC25A1 protein abundance as indicated by Western Blotting analysis carried out on 
cultured skin fibroblasts of the affected brother and control cells (Fig. 3). No evidence of 
altered mitochondrial content or network morphology was observed (Supplementary Figure 
4A) and a small (not significant p > 0.05) decrease of mitochondrial membrane potential 
was measured in patient fibroblasts compared to control cells (Supplementary Figure 4B).
We have recently developed an in silico approach to measure the evolutionary constraint 
acting on each amino acid residue of the human mitochondrial carriers and, consequently, to 
predict its importance in preserving the carrier function [25]. Considering all the 216 
residues previously scored for SLC25A1 [25], R247 is in the bottom 50% of scores, i.e. 
below a median threshold of 4.68. It is worth noting that all other known mutated residues in 
SLC25A1-associated pathology have higher scores, including the previously biochemically 
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characterized p.G130D and p.R282H (Table 2, Fig. 4). According to this scoring method, 
the R247 residue of SLC25A1 is predicted to be less functionally relevant than other 
mutated SLC25A1 residues, consistent with a milder clinical phenotype, normal levels of 
urinary 2-hydroxyglutarate and higher protein activity (Table 2).
Zebrafish SLC25A1 knockdown
To explore the effect of reduced expression of SLC25A1 on the neuromuscular junction, we 
knocked down the 2 SLC25A1 orthologues (SLC25A1a and SLC25A1b) that are expressed 
in zebrafish embryos, by injection of antisense MOs. Mis-spliced transcripts were detected 
alongside the wild-type transcript at 48hpf following injection of both SLC25A1a and 
SLC25A1b MOs (Supplementary Figure 5).
Knockdown of neuromuscular junction proteins usually affects motility and swimming 
behaviour of injected embryos. Indeed, MO-injected embryos displayed altered tail 
morphology (Fig. 5), and swimming and touch-evoked escape responses at 48 hpf were 
impaired. Histologically, we observed normal muscle morphology while NMJ development 
was abnormal (Figs. 6, 7). Motor axon terminal showed short and erratic outgrowth toward 
the muscle fibre with no evidence of complete synapse formation, pointing towards an 
underlying presynaptic defect (Fig. 6). NMJ morphology and function were normal in 
embryos injected with a standard control MO and in non-injected wild type embryos (data 
not shown). In addition, knockdown embryos often showed oedema of the hindbrain, heart, 
yolk sac and tail (Fig. 5, Supplementary Figure 6). Abnormal heart development was 
observed with increased severity of phenotype with reduced blood flow to the tail 
(Supplementary video). Knockdown embryos displayed these characteristics in both the 
presence and absence of the apoptotic suppressing anti-p53 MO (Supplementary Figures 7, 
8).
DISCUSSION
The diagnosis of congenital myasthenia is based on the presence of early onset fatigable 
weakness, impaired NMJ transmission, absence of auto antibodies and response to treatment 
[5, 31]. The two affected siblings in our study had clinical features consistent with CMS in 
addition to variable intellectual disability, which is uncommon in CMS. The presence of the 
high proportion of pairs showing jitter and the significant blocking on SFEMG, indicated a 
problem with neuromuscular transmission and thus a contributing NMJ disorder.
It is worth noting that the disease course in these two patients was relatively mild compared 
to other CMS patients [2], with little evidence of progression.
The X chromosomal deletion identified in the female, but not the male patient could have 
contributed to her intellectual disability. This is a large heterozygous deletion (30 Mb), 
which contains 273 genes (full gene list available on request), including FMR1, which is 
responsible for fragile-X-syndrome. In a male individual, a contiguous gene syndrome with 
a much more severe or probably lethal phenotype would be expected.
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We performed homozygosity mapping and whole exome sequencing to determine the 
underlying genetic cause in our family and successfully identified a novel homozygous 
mutation in the SLC25A1 gene. This was the only, novel variant affecting a highly 
conserved residue, that was expressed in muscle and nerve and predicted to be disease 
causing. Further corroborating evidence arose from demonstration of a NMJ defect in a 
previously described patient with a different compound heterozygous mutation of SLC25A1 
gene [17]. The phenotype of the latter was associated with a neurodevelopmental disorder 
manifesting as profound psychomotor retardation, hypotonia, apnoeic crises, poor feeding, 
epilepsy, postnatal microcephaly, sensori-neural deafness, agenesis of the corpus callosum 
(ACC) and hypoplastic optic nerves. She had raised urinary hydroxyglutaric acid levels and 
Krebs metabolites [17].
In addition, a subsequent report described a series of 13 patients, from 12 unrelated families, 
with a severe clinical phenotype and recessive SLC25A1 mutations [18]. 8 of these patients 
were deceased a few months after birth (range 1 month - 5 years 1 month). All exhibited 
developmental delay, hypotonia and seizures [18].
A large peak of 2 hydroxyglutaric acid was identified in all patients previously reported with 
SLC25A1 mutations, but no variants were identified in corresponding genes causing L2 or 
D2 hydroxyglutaric aciduria, suggesting that this metabolic disturbance is secondary to 
defects in SLC25A1. We have tested our 2 patients and found normal urinary organic acid 
analysis in keeping with a milder phenotype. SLC25A1 is well conserved across species and 
was shown to be critical in intermediary metabolism, glucose induced insulin secretion and 
chromatin integrity [13, 14, 28, 32]. The chromosomal location of this gene (22q11.2) also 
attracted some attention as this is either translocated or amplified in some tumours and 
deleted in DiGeorge syndrome and possibly schizophrenia [33, 34]. However, until recently, 
SLC25A1 was not directly linked to any human disease [17, 18].
Knockdown of several CMS genes in zebrafish embryos has been recently used to 
demonstrate direct or indirect effects on the neuromuscular junction [35, 36]. Interestingly, 
SLC25A1 knockdown showed variable phenotype ranging from mild, moderate to severe; 
with confirmed aberrant NMJ development and function similar to what was seen in the 2 
affected siblings. At the level of the neuromuscular junction, we were able to show intact 
muscle fibre architecture with clearly abnormal nerve outgrowth and synapse formation. 
This indicates that SLC25A1 is required for normal NMJ formation. Of note, an SLC25A1 
knockdown zebrafish model was previously generated to show the influence of SLC25A1 
on embryogenesis, mitochondrial DNA and autophagy; but limited details of the fish 
phenotype and NMJ development were provided [14]. In addition to the NMJ abnormalities, 
we demonstrate further alteration in brain and heart morphology and development in the 
more severely affected zebrafish morphants, compatible with a more general function of 
SLC25A1 in mitochondria.
The mutation identified in this study (p.R247Q) has a less deleterious effect when compared 
to other SLC25A1 mutations described to date [17, 18]. This is supported by the observed 
preserved protein expression in patient’s skin fibroblast with moderately reduced carrier 
function and the low score from in silico prediction.
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In spite of a relevant difference between the scores of R247 and other previously reported 
mutated residues like G130 [17], the activity of the yeast orthologous protein harboring 
either of the two pathogenic mutations at equivalent positions is only 15% different, i.e. 40% 
and 25%, respectively (Table 2 and Fig. 3). Such observation may be the consequence of 
two possible factors. First, the yeast model system may not exactly reproduce the real 
activity of the human mutated proteins. Although this cannot be excluded, it appears 
unlikely since the yeast ortholog closely mirrors SLC25A1 for both protein sequence and 
citrate transport activity. Furthermore, as far as the clinical phenotype is concerned, it is 
worth recalling that the p.G130D mutation is heterozygous and the other affected allele 
harbors the p.R282H mutation [17] which completely abolishes transport activity (Fig. 4). 
Second, the score is an evolutionary based value, which relies on the strength of natural 
selection and depends on the fitness of organisms, i.e. the likelihood of organisms to survive 
and generate fertile progeny [37]. The present patients reached the reproductive age and they 
may be considered fertile even if the protein activity of the p.R247Q mutant is partially 
reduced. For this reason the score of p.R247Q is expected to be much lower compared to 
any other examined SLC25A1 mutation that is instead responsible for premature death in 
neonatal age. At the same time, this might explain why G130 and R282 [17] as well other 
previously reported pathogenic mutations [18] have very close scores.
We speculate that this mild manifestation of disease may have facilitated the detection of an 
NMJ defect in our patient, while it remains undetected in patients with the more disabling, 
often fatal form of the disease. Further studies are required to elucidate why the NMJ seems 
to be particularly sensitive to mild SLC25A1 dysfunction, while other organs such as the 
brain remain largely asymptomatic. Interestingly, the knockdown experiments in zebrafish 
show a similar dependency of symptoms in relation to the knockdown: less severely affected 
zebrafish morphants show motility defects and NMJ abnormalities, but more severely 
affected morphants have additional defects of the brain and heart compatible with a 
generalized mitochondrial defect.
Mitochondria are ubiquitous organelles that intervene in a multitude of cellular functions 
including energy production, cellular metabolism, calcium homeostasis and apoptosis [10, 
11]. The exact role of mitochondria in synapse development remains poorly understood and 
is likely to be complex. How defects in a ubiquitous mitochondrial citrate carrier can 
manifest primarily as a NMJ defect remains to be determined.
It is also worth emphasizing that SLC25A1 is likely to be a very rare cause of a pure CMS 
phenotype. We have screened undiagnosed CMS patients from our extended cohorts and did 
not detect additional pathogenic SLC25A1 variants. Exome sequencing results from more 
than six thousand random individuals (Exome Variant Server; http://evs.gs.washington.edu/
EVS/, accessed April 2014), revealed only 15 missense mutations in SLC25A1. Each 
mutation is heterozygous and present in less than 0.1% of the screened population. At least 
seven of these mutations are predicted to severely impair the protein function according to 
our scoring system and represent an existing source of pathogenic alleles circulating in the 
human population. Therefore, while the presence of homozygous mutations or compound 
heterozygous mutations in SLC25A1 is a rare event, should a patient show fatigable 
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weakness, one may wish to test for SLC25A1 mutations and consider screening for cardiac 
and metabolic defects should this be proven to be culprit.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Sequence alignment of mitochondrial citrate carrier (SLC25A1) from different organisms 
(panel A) and other members of mitochondrial carrier family (panel B). Accession numbers 
for each species/carrier is given. Panel C shows structural comparative model of human CIC 
and docking of citrate. The 3D comparative model of human CIC is reported in white 
cartoon representation. The six transmembrane helices are indicated by black labels (H1-
H6). Two of the three helices parallel to the membrane planes are also labelled (h12 and 
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h56). The citrate ligand is shown in cyan licorice. The pathogenic mutations p.R247Q (this 
work), p.G130D, p.R282H [17] are displayed in red surf representation.
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Fig. 2. 
Functional characterization of the wild-type (WT) and the p.R241Q Ctp1. The uptake rate of 
(14C) citrate was measured by adding 0.1 mM of (14C) citrate to proteoliposomes 
reconstituted with purified WT or with the mutated Ctp1 protein. The proteoliposomes were 
preloaded internally with 10 mM of citrate. The means and SDs from five independent 
experiments are shown (*p < 0.01, two-tailed unpaired Student’s t-test).
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Fig. 3. 
Total lysates of fibroblast cells (patient and control) were subjected to Western blot analysis 
upon separation by SDS-PAGE and SLC25A1 (~31-kDa) and β-ATPase (~55-kDa) levels 
were determined by densitometric analysis. The relative ratio was calculated and the means 
and SDs from three independent experiments are shown (*p < 0.01, two-tailed unpaired 
Student’s t-test).
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Fig. 4. 
Transport assay of reconstituted CTP1p wild type (WT) and mutated Ctp1p forms into 
liposomes. At time zero 0.1 mM (14C) citrate was added to liposomes reconstituted with the 
recombinant wild-type or mutants and containing 10 mM citrate. At the indicated times, the 
uptake of the labeled substrate was terminated by adding 20 mM pyridoxal 5′-phosphate and 
20 mM bathophenanthroline. Similar results were obtained in four independent experiments.
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Fig. 5. 
Live embryos imaged at 48hpf following co-injection of SLC25A1a (5 ng) and SLC25A1b 
(2.5 ng). Injected embryos demonstrate a range of phenotypes with mild to severe 
morphological abnormalities. Embryos exhibit a developmental delay with curvature and 
shortening of the tail and also oedema of the hindbrain, heart, yolk sac and tail. Scale bars: 
500 μm.
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Fig. 6. 
Neuromuscular junctions following injection with SLC25A1 MOs. Non-injected control 
Wild Type Golden embryos (left) and SLC25A1 MO injected embryos were stained for 
postsynaptic AChR (α-bungarotoxin, red staining) and presynaptic nerve endings (SV2 
antibody, green staining). Combined SLC25A1 MO (a 5 ng & b 2.5 ng) injected 48hpf 
embryos demonstrate short motor axons and erratic outgrowth toward the muscle fibre. 
Scale bar: 50 μm.
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Fig. 7. 
Muscle morphology following injection with SLC25A1 MOs. WT and control MO injected 
embryos (left) and SLC25A1 MO injected embryos (centre and right) were stained for F-
actin with Alexa Fluor® 594 conjugated phalloidin (5 μg/ml). WT embryos and those 
injected with a standard control MO showed normal muscle morphology. Combined 
SLC25A1 MO with and without the addition of anti-p53 MO also demonstrate normal 
muscle morphology. Scale bar: 50 μm.
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Table 1
Clinical features of the 3 patients with mutations in the SLC25A1 gene presenting with a phenotype suggestive 
of congenital myasthenia
Case 1 Case 2 Case 3
Gender/age/ethnicity Male/33y/English Female/19y/English Female/18 m/Israeli
Mutation p.R247Q p.R247Q p.G130D; p.R282H
Progression Stable with some long term 
fluctuations
Stable progressive
Age at onset Less than 2 years Less than 2 years 10 days
Symptoms at onset Fluctuating leg weakness Fluctuating arm and leg 
weakness
Poor suck, hypotonia, apneas
Psychomotor delay/intellectual disability No but developed obsessive 
compulsive disorder in adulthood
Yes Yes
Ocular involvement Ptosis Ptosis Optic nerve hypoplasia
Bulbar weakness No No Yes
Apneic crises No No Yes
Epilepsy No No Yes
Agenesis of the corpus callosum No No Yes
Hearing loss No No Yes
Elevated urinary organic acids No No Yes
Abnormal jitter with block Yes Not done Yes
Positive response to treatment Yes Equivocal No
J Neuromuscul Dis. Author manuscript; available in PMC 2016 February 09.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Chaouch et al. Page 27
Table 2
Phenotype and mutations of patients affected by SLC25A1-associated pathologies [17, 18]. A prediction of the 
functional relevance of each residue is also reported (residue-specific score), as calculated in [25]. (a) agenesis 
of the corpus callosum and optic nerve hypoplasia with marked jitter on SFEMG(b) neonatal epileptic 
encephalopathy and absence of developmental progress. (c) Percentage of activity of the mutated yeast 
orthologous protein compared to the yeast wild-type protein [[17] and this study]. (d) Percentage of citrate 
export from human mutated fibroblasts compared to human control fibroblasts [18]. 2-HG: urinary 2- 
hydroxyglutarate
Patients Clinical phenotype 2-HG levels Human mutation SLC25A1 Activity (%) Residue-specific score
Present study mild Normal p.R247Q 40 (c) 3.38
[17] severe (a) High p.G130D 25 (c) 5.50
p.R282H 0 (c) 5.61
[18] patient 1 severe (b) High p.S193W 12.9 (d) 5.51
[18] patient 2 – High p.R282G 12.3 (d) 5.61
[18] patient 3 severe (b) High p.R282C 6.1 (d) 5.61
[18] patient 5 severe (b) High p.G167R 19.8 (d) 5.10
[18] patient 6 severe (b) High p.P45L – 5.00
[18] patient 8 severe (b) High p.E144Q – 5.04
[18] patient 10 severe (b) High p.M202T – 5.33
p.Y297C – 4.89
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